Sid Jain, a leader on the pharmaceutical R&D data science team at Johnson & Johnson, knows that new and better treatment options change lives. And being a Crohn's disease patient himself has supercharged his mission to help revolutionize the research process.
Mobilizing to help coworkers in need. Increasing diverse representation in clinical trials. Advocating on behalf of people living with life-altering medical conditions. Learn about the extraordinary ways these trailblazers made a difference in 2022.
What do diseases like multiple myeloma and lupus have in common? They're more prevalent in people of color—yet historically these patients have been left out of clinical research, often to dire health consequences. Learn how Johnson & Johnson is working to make the study of conditions like these more equitable.
Tackling health inequities. Pinpointing the sources of pain. Helping the immune system target cancer. These are just some of the ambitious goals of the companies residing at Johnson & Johnson's newest incubator, JLABS @ Washington, DC. Meet three healthcare innovators leading the way.
Algorithms, artificial intelligence, machine learning and other technologies are transforming the way physicians identify, treat and manage diseases. Here’s how Johnson & Johnson is putting the latest tools to work.
If people of color aren't well represented in healthcare, then communities of color cannot receive truly equitable healthcare. These unique programs are supporting physicians from racial minority groupsso they can better support the patients who need them.
With COVID-19 dominating the news this year, chances are you've also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.
The novel coronavirus has exposed deeply rooted disparities across the healthcare system which disproportionately impact communities of color. The way to begin to pave the way for lasting change? Inclusive innovation, community outreach and policy work—and a passion for fighting for an equitable future.
Njira Lugogo, M.D., is a pulmonologist at the University of Michigan who is leading a clinical study of an investigational COVID-19 vaccine candidate. She helps answer common questions people may have about the process, from what people over 60 need to know to how participants are being kept safe during the pandemic.
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
The U.S. has one of the highest maternal mortality rates in the developed world, with women of color especially at risk. Dr. Robyn R. Jones, Senior Medical Director at Johnson & Johnson, is determined to change that and find ways to address this urgent crisis.
For World AIDS Day, three attendees of the virtual 2020 International AIDS Society Conference, including activist and actress Laverne Cox, talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
From scientists working on a potential vaccine to medically trained employees who mobilized to the front lines to help treat patients, these men and women share what most resonates for them about the unique and devastating virus, both professionally and personally.